12:00 AM
Feb 28, 2000
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Alprox-TD: Began Phase II testing

NexMed Inc. (NEXM), Robbinsville, N.J.
Product: Alprox-TD
Business: Reproductive, Drug delivery
Therapeutic category: Vasodilation
Target: Smooth muscle cells...

Read the full 80 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >